AU2008297660A1 - Peptide-lipid constructs and their use in diagnostic and therapeutic applications - Google Patents
Peptide-lipid constructs and their use in diagnostic and therapeutic applications Download PDFInfo
- Publication number
- AU2008297660A1 AU2008297660A1 AU2008297660A AU2008297660A AU2008297660A1 AU 2008297660 A1 AU2008297660 A1 AU 2008297660A1 AU 2008297660 A AU2008297660 A AU 2008297660A AU 2008297660 A AU2008297660 A AU 2008297660A AU 2008297660 A1 AU2008297660 A1 AU 2008297660A1
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- lipid construct
- group
- chch
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 153
- 238000000034 method Methods 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 60
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 51
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 43
- 101150065749 Churc1 gene Proteins 0.000 claims description 43
- 102100038239 Protein Churchill Human genes 0.000 claims description 43
- 150000001768 cations Chemical class 0.000 claims description 36
- 210000002966 serum Anatomy 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 20
- 210000002257 embryonic structure Anatomy 0.000 claims description 19
- 125000006850 spacer group Chemical group 0.000 claims description 19
- 102100026801 Glycophorin-E Human genes 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 108091005250 Glycophorins Proteins 0.000 claims description 16
- 230000004520 agglutination Effects 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 102000006395 Globulins Human genes 0.000 claims description 12
- 108010044091 Globulins Proteins 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 102100036430 Glycophorin-B Human genes 0.000 claims description 8
- 108010084094 alanyl-alanyl-alanyl-alanine Proteins 0.000 claims description 8
- -1 peptide 30 lipid Chemical class 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- QWJIUYWHYILJMQ-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound CCC(C(O)=O)N1C(=O)C=CC1=O QWJIUYWHYILJMQ-UHFFFAOYSA-N 0.000 claims description 2
- MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 241000871434 Pegia Species 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 description 56
- 210000003743 erythrocyte Anatomy 0.000 description 38
- 239000002502 liposome Substances 0.000 description 27
- 239000002202 Polyethylene glycol Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000012528 membrane Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009582 blood typing Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000006353 oxyethylene group Chemical group 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 210000004340 zona pellucida Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 1
- 101100017588 Arabidopsis thaliana LIF2 gene Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 101100079811 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NEJ1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical class OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003003 phosphines Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
- G01N33/5304—Reaction vessels, e.g. agglutination plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Description
WO 2009/035347 PCT/NZ2008/000239 1 PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC. AND THERAPEUTIC APPLICATIONS TECHNICAL FIELD 5 The invention relates to methods for effecting qualitative and quantitative changes in the levels of peptide expressed at the surface of cells and multi-cellular structures, and constructs for use in such methods. 10 In particular, the invention relates to peptide-lipid constructs for use in diagnostic and therapeutic applications, including serodiagnosis. 15 BACKGROUND ART The ability to effect qualitative and quantitative changes in the level of peptides expressed at the surface of cells and multi-cellular structures provides for a range of diagnostic 20 and therapeutic applications. Qualitative and quantitative changes in the level of peptides expressed at the surface may modify trans-membrane transport, cell-solute and cell-cell interactions, and thus the 25 functionality of the. modified cell or multi-cellular structure. Known methods of effecting such changes include gene manipulation, chemical modification of endogenous membrane 30 peptides, and "cell surface painting" using lipid anchors such as GPI.
WO 2009/035347 PCT/NZ2008/000239 2 The specification accompanying international application number PCT/NZ2005/000052 (publication number WO 2005/090368) describes the preparation of water soluble carbohydrate-lipid constructs for use in methods of effecting qualitative and 5 quantitative changes in the level of carbohydrates expressed at the surface of cells and multicellular structures. The specification accompanying international application number PCT/NZ2006/000245 (publication number WO 2007/035116) 10 describes another method for the preparation of water soluble carbohydrate-lipid constructs where the carbohydrate is the polymer hyaluronic acid. Use of the construct to modify embryos and promote association with endometrial cells is described. 15 Relatively little work has been performed on the site-directed coupling of peptides to phospholipids as individual components prior to. their incorporation in self assembling lipid structures, such as liposomes, or as would be required to 20 provide peptide-lipid constructs for use in methods of effecting qualitative and quantitative changes in the level of peptide expressed at the surface of cells and multicellular structures. 25 A variety of standard techniques have been described for the covalent coupling of peptides to liposomes surfaces. Martin et al (1990) has reviewed methods of attaching moieties including peptides, to the surface of liposomes. 30 Blume et al (1993) describes the coupling of the water soluble Glu-plasminogen to liposomes by the method described by Kung and Redemann' (1986). The chemical ECDI (1-ethyl- (3- WO 2009/035347 PCT/NZ2008/000239 3 dimethylaminopropyl) carbodiimide hydrochloride) is used to activate the liposomes prior to incubation of the activated liposomes suspension with Glu-plasminogen. Proteo-PEG-coated liposomes with Glu-plasminogen covalently attached to the ends 5 -of the distearylyphosphatidylethanolamine (DSPE)-PEG-COOH are provided. Haselgrnbler et al (1995) describes a heterobifunctional crosslinker used to facilitate the preparation of 10 immunoliposomes. The crossllinker is synthesised from a diamine derivative of poly(ethylene glycol) (PEG, average molecular weight 800 dalton (18mer)). The crosslinker has 2 (pyridylthio)propronyl (PDP) and N-hydroxysuccinimide ester (NHS) as functional groups. 15 Ishida et al (2001) describes the preparation of liposomes bearing polyethylene glycol-coupled transferrin. Transferrin was conjugated via the terminal carboxyl residue of DSPE-PEG COO. The liposomes were proposed as having utility in in 20 vivo cytoplasmic targeting of chemotherapeutic agents or. plasmid DNAs to target cells. Massaguer et al (2001) describes the incorporation of a peptide sequence (GGRGRS) and hydrophobic derivatives to the 25 surface of chemically activated liposomes. The incorporation was carried out through the carboxyl group of N-glutaryl dipalmitoyl phosphatidyl choline (NGPE). Massaguer et al (2001) noted that considering potential in 30 vivo applications, where sterility and simplicity would be some of the most important requirements, processes based on chemical reactions on the surface of liposomes inv living extra steps would be more difficult to be scaled up at the WO 2009/035347 PCT/NZ2008/000239 4 industrial level. A hydrophobic derivative of the peptide sequence was identified as providing optimal properties for incorporation to the surface of liposomes. 5 Chung et al (2004) describe the antigenic determinant shielding effect of DOPE-PEG incorporated into the membranes of cells and speculated concerning the potential of lipid PEG(n) (s) to regulate biological cell responses and the extension of this concept to the introduction of functional 10 molecules at the end of the PEG chain. Kato et al (2004) describe a method for anchoring of macromolecular proteins into the membranes of living mammalian cells. A dioleylphosphatidylethanolamine (DOPE) derivative 15 coupled with hydrophilic polyethylene glycol) (PEG80) was used as the synthetic membrane anchor. Peptides were conjugated at the distal terminal of the PEG moiety via an amino-reactive N-hydroxysuccinimide derivative of the synthetic membrane anchor. 20 The PEG80 moiety facilitated solublisation of the synthetic membrane anchor in water. As noted by Kato et al (2004) if the anchor is insoluble in water, undesirable and complicated processes such as liposome preparation and the fusion of 25 liposomes with the cell membrane may be required to anchor the conjugates into the cell membrane. An additional advantage noted by Kato et al (2004) was that synthetic membrane anchors with high hydrophile-lipophile 30 balance values (attributable to PEG spacer with a high number of oxyethylene units) were concluded to have no cytolytic .activity. However, difficulties arisN in the use of synthetic WO 2009/035347 PCT/NZ2008/000239 5 membrane anchors including a PEG spacer with a high number of oxyethylene units. Firstly, the expression of the conjugative peptide or other 5 endogenous cell surface peptides may be masked by the PEG spacer. Secondly, a PEG spacer with a high number of oxyethylene units may elicit non-specific adherence of protein (including antibodies in certain individuals) and/or the non specific activation of the complement cascade. 10 Winger et al (1996) describes the conjugation of bromoacetylated DSPE with a thiol terminated decapeptide comprising at its C-terminus the minimal human thrombin receptor peptide agonist (HS---SerPheLeuLeuArgAsn). 15 Hashimoto et al (1986) describes the conjugation of iodoacetylated DSPE with thiolated compounds. A need exists for peptide-lipid constructs that can be used to 20 effect qualitative and quantitative changes in the level of peptides expressed at the surface of cells and multi-cellular structures. It is an object of this invention to provide peptide-lipid 25 constructs that satisfy this need or at least provide a useful choice. DISCLOSURE OF INVENTION 30 In a first aspect the invention provides a method of detecting reactive antibody in the serum of a subject including the steps of: WO 2009/035347 PCT/NZ2008/000239 6 e Contacting a sample of the serum with a suspension of cells modified to incorporate a peptide-lipid construct of the structure (L-S-)iF (-S-L)j to provide a mixture; 5 e Incubating the mixture for a time and at a temperature sufficient to allow agglutination; and * Determining the degree of agglutination of the cells in the mixture; 10 where: F is a peptide comprising an epitope for the reactive antibody; 15 S is a spacer covalently linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids; and i and j are independently 0 or 1, 20 Optionally, the method includes the preliminary step of: * Adding an amount of the peptide to the sample of the serum; 25 where the amount of the peptide is sufficient to neutralize non-specific agglutination or confirm specificity of the reactive antibody.
WO 2009/035347 PCT/NZ2008/000239 7 Optionally, the method includes the intermediate step-of: Adding an anti-subject globulin antibody to the mixture prior to determining the degree of agglutination of the 5 cells of the mixture. Preferably, the subject is a human. Preferably, the cells are red blood cells. 10 Preferably, the anti-subject globulin antibody is anti-human globulin (AHG) antibody. Preferably, the reactive antibody is reactive to an antigen 15 selected from the group consisting of: Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood group system). The spacer (S) is selected to provide a water soluble peptide 20 lipid construct. Preferably, S is a spacer covalently linking F to L via an oligomer of ethylene glycol. 25 Preferably, the structure of the peptide-lipid construct includes the substructure: 0 0 0O 0-MO NH NH
*CM
WO 2009/035347 PCT/NZ2008/000239 8 where M is a monovalent cation (M+), n is 6 to 14 and * is other than H. More preferably, the structure of the peptide-lipid construct 5 is either: 0 0 0 (Xa),Cys (Xaa)~ * O O O- -O NH )NH (C 3 N OI n * 0 0 or 10 0 0 0 NHfO'(Xaa)z 0or -P-0 NE 0--Y o OM 0 * o 0 where M is a monovalent cation (M+), n is 6 to 14, w is 1 or 2, the sum of x and y is greater than 5, z is greater than 5, 15 and * is other than H. Preferably, the sum of i and j is 1. Optionally, F is a peptide including a proximal terminal 20 sequence (PTS) selected to promote solubility of the peptide.
WO 2009/035347 PCT/NZ2008/000239 9 In a preferment of this option, the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 5 Preferably, F is a peptide comprising an epitope of antigens selected from the group consisting of: Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood group system). 10 More preferably,. F is a peptide selected from the List of Peptides. Most preferably, F is a peptide selected from the group consisting of: 15 GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValCys SerGlnThrAsnAspLysHisLysArgAspCys AlaAlaAlaAlaValMetTyrAlaSerSerGly GlySerGlySerGlyValMetTyrAlaSerSerGly Preferably, L is a glycerophospholipid.. More preferably, L is a glyQerophospholipid selected from the group consisting of: 1, 2-0-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) WO 2009/035347 PCT/NZ2008/000239 10 and 1,2-0-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE). Preferably, the peptide-lipid construct is an exemplifying 5 embodiment of the second or third aspect of the invention. In a second aspect the invention provides a peptide-lipid construct of the structure: 10 L-S-F where F is a peptide; 15 S is a spacer covalently linking F to L via an oligomer of ethylene glycol; and L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids. 20 Preferably, the structure of the peptide-lipid construct includes the substructure: 00 * o- -o NH NH * 0 25 where M is a monovalent cation (M*), n is 6 to 14 and * is other than H. Optionally, F is a peptide including a proximal terminal 30 sequence (PTS) selected to promote solubility of the peptide.
WO 2009/035347 PCT/NZ2008/000239 11 In a preferment of this option, the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 5 Preferably, the terminal sequence of the peptide is selected from the group consisting of: GlyLysLysLysLysSerCys AlaAlaAlaAlaCys GlySerGlySerGlyCys CysSerLysLysLysLysGly CysAlaAlaAlaAla CysGlySerGlySerGly 10 Preferably, S is covalently linked to F via a sulphide bond formed with the Cys residue of the peptide. More preferably, S is covalently linked to F via a sulphide bond formed with a Cys residue of the peptide at or proximal 15 to a terminus of the peptide. Most preferably, S is linked to F via a sulphide bond formed with a Cys residue of the peptide at the carboxy-terminus of the peptide. 20 The spacer (S) is of the structure S 1
-S
2
-S
3 and selected to provide a water-soluble peptide-lipid construct. Sj, is an oligomer of ethylene glycol.
WO 2009/035347 PCT/NZ2008/000239 12 Preferably, S 2 rS 3 is selected from the group consisting of: 0 o NH
(CH
2 )N R2 0 5 where Ri is a terminal carbon of Si, R 2 is the sulphur of the Cys residue and w is 1 or 2. Preferably, the structure of the peptide-lipid construct is: 10 (Xaa).C rs (Xaa), 0 00 * 0 0 O O-- NH NH (CH 2 ) S * ON *0 oM O where M is a monovalent cation (M*), n is 6 to 14, w is 1 or 2, the sum of x and y is greater than 5, and * is other than 15 H. More preferably, n is 6. Most preferably, y is 0. Preferably, F is a peptide comprising an epitope of antigens selected from the group consisting of: Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood 20 group system). More preferably, F is a peptide selected from the List of Peptides.
WO 2009/035347 PCT/NZ2008/000239 13 Most preferably, F is a peptide selected from the group consisting of: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlycys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValCys SerGlnThrAsnAspLysHisLysArgAspCys 5 Preferably, L is a glycerophospholipid. More preferably, L is a glycerophospholipid selected from the group consisting of: 1, 2 -0-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1, 2 -0-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE). 10 In an exemplifying first embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys 0 0 0 CH 0
CH
3
(CH
2 ) 7 CHCH (CH2) 0-11 NH 64NH N s 6
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 0 0 15 where M is a monovalent cation (M+) and designated DOPE-PEG 6 PAla-Mal-PTS-lMUTK) (Ml).
WO 2009/035347 PCT/NZ2008/000239 14 In an exemplifying second embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCy 0 0o 0 00 CH3 (CH2) 7CHCH (CH2) 3 0 - 0 N O NH CH3 (CH2) 7CHCH (CH2) 3I 0 O where M is a monovalent cation (M+) and designated DOPE-PEG6 - Ala-Mal-PTS-2MUTK) (M2) . In an exemplifying third embodiment of the second aspect the 10 invention provides a peptide-lipid construct of the structure: GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCys 0 0 0
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 - 0 NH O NH N
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 O OM O 0 where M is a monovalent cation (M+) and designated DOPE-PEG 6 15 fpAla-Mal-PTS-3MUTM(M3). In an exemplifying fourth embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: SerSerGlnThrAs nAspLysHisLysArgAspThrTyrCys O 0 0
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 r o - O INO 6H
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 O 0 0 20 0 where M is a monovalent cation (M+). and designated DOPE-PEG 6 $Ala-Mal-13MUTK(M13).
WO 2009/035347 PCT/NZ2008/000239 15 In an exemplifying fifth embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: ProAlaHisThrAlaAsnGluValCys 0 0 0 01 CH3 (CH 2
)
7 CHCH (CH 2 ) 3o I _,NH O NH N
CH
3
(CHI
2 ) 7 CHCH (CH 2 ) 3 fO 0 5 0 where M is .a monovalent cation (M*) and designated DOPE-PEG 6 SAla-Mal-18Mur (M18) (n=6). 10 In an exemplifying sixth embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: SerGlnThrAsnAspLysHisLysArgAspCys 0 0 0 0I
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 -- O NH NH N I n
CH
3
(CHI
2 ) 7
CHCH(CH
2 ) Or OM 0 0 15 where M'is a monovalent cation (M*) and designated DOPE-PEG 6 @Ala-Mal-21MUTK(M21) (n=6). In an exemplifying seventh embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: 20 GluGluThrGlyGluThrGlyGlnLeuValCy 0 0 01 0 i PO O4O
CH
3
(CH
2 ) 7 CHCH ( CH23 0--0 NH O NH N s
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 0 0 WO 2009/035347 PCT/NZ2008/000239 16 where M is a monovalent cation (M*) and designated DOPE-PEG 6 SAla-Mal-Hil3 (M23) (n=6). In an exemplifying eighth embodiment of the second aspect the 5 invention provides a peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrSerSerGlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCy 1 0 0 0
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 O - -O NH O NH N
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 0 0 0 where M is a monovalent cation (M+) and designated DOPE-PEG 6 10 PAla-Mal-PTS-Milt(K,M). In an exemplifying ninth embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrCy 0 0 0 0 . CH3 (CH2) 7CHCH (CH2) 3 0 0 NH OAN 0-P-0 NH\ H
CH
3
(CH
2 ) 7 CHCH (CH 2 ) 3 M 15 0 where M is a monovalent cation (M+) and designated DOPE-PEG 6 PAla-Mal-Milt(K) (MOO). 20 In an exemplifying tenth embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: GlnThrAsnAspMetHisLysArgAspThrTyrCy 0 0 0
CH
3
(CH
2
)
7 CHCH (CH 2 3 O -N H
CH
3
(CH
2 7 CHCH (CH2 3 0 6 0 WO 2009/035347 PCT/NZ2008/000239 17 where M is a monovalent cation (M*) and designated DOPE-PEG 6 PAla-Mal-Milt (M) 5 In an exemplifying eleventh embodiment of the second aspect the invention provides a peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrSerSerGlnThrAsnAspMetHisLysArgAspThrTyrCy CH3(CH2)7CHCH(CH2) 0 0 i -O N
CH
3
(CH
2
)
7 CHCH(CH2 3 0 OM0O' O 10 where M is a monovalent cation (M+) and designated DOPE-PEG 6 PAla-Mal-Milt(K,M). In a third aspect the invention provides a peptide-lipid 15 construct of the structure: L-S-F where 20 F is a peptide; S is a spacer covalently linking F to L via an oligomer of ethylene glycol; and L is a lipid selected from the.group consisting of 25 diacyl- and dialkyl-glycerolipids, including glycerophospholipids.
WO 2009/035347 PCT/NZ2008/000239 18 Preferably, the structure of the peptide-lipid construct is: 0 * 0 (Xaa)z 0-P- 0H o oM o * 0 0 5 where M is a monovalent cation (M+), n. is 6 to 14, z is greater than 5, and * is other than H. More preferably, n is 14. Optionally, F is a peptide including a terminal sequence 10 selected to promote solubility of the peptide. In a preferment of this option, the terminal sequence of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 15 Preferably, F is a peptide selected from the group consisting of: (Xaa)zValMetTyrAl'aSerSerGly; 20 where z is the integer 4, 5 or 6.
WO 2009/035347 PCT/NZ2008/000239 19 Preferably, F-is a peptide selected from the group consisting of: SerLysLysLysLysGlyValMetTyrAlaSerSerGly AlaAlaAlaAlaValMetTyrAlaSerSerGly GlySerGlySerGlyValMetTyrAlaSerSerGly 5 Preferably, L is a glycerophospholipid. More preferably, L is a glycerophospholipid selected from the group consisting of: 1,2-0-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1, 2 -0-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE). 10 In an exemplifying first embodiment of the third aspect the invention provides a peptide-lipid construct of the structure:
CH
3
(CH
2
)
7 CHCH (CH 2 )3 0o 0 - ' NH- OGlySerGlySerGlyValMetTyrAlaSerSerGly CH3 (CH 2 ) 7 CHCH (CH 2 )3KO OM O 0 15 where M is a monovalent cation (M+) and designated DOPE-PEG 1 4 Syph. In a fourth aspect the invention provides a method of 20 preparing a peptide-lipid construct (F-S-L) of the second aspect of the invention.including the steps of: e Preparing a maleimido-derivative of a precursor construct by reacting a maleimido-donating reagent with a precursor 25 construct of the structure L-Si-NH 2 ; and WO 2009/035347 PCT/NZ2008/000239 20 Reacting the maleimido-derivative of the precursor construct with a peptide (F) including a Cys residue and solubilised in a solvent. 5 where: L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids; and 10 Si is selected from the group consisting of oligomers of ethylene glycol. Preferably, the structure of the peptide-lipid construct is: 15 (Xaa).C s(Xaa)y 0 0 o + 0 0 o o NH O NH (CH 2 )N I n * 0 o 0 where n is 6 to 14, w is 1 or 2, the sum of x and y is greater than 5, and * is other than H. 20 Preferably the maleimido-donating reagent is selected from the group consisting of: N-oxysuccinimid ester of maleimidobutyric acid; and N-oxysuccinimid ester of maleimidopropionic acid 25 Preferably, Si is an oligomer of ethylene glycol selected from the group consisting of 6 to 14 mer PEG (PEG 6 to PEG 1 4 ) . Most preferably, Si is PEG 6
.
WO 2009/035347 PCT/NZ2008/000239 21 Preferably, the solvent-is selected from the group consisting of: trifluoroethanol; DMSO; or mixtures thereof.
Preferably, the Cys residue is a terminal Cys residue. 5 Optionally, F is a peptide including a proximal terminal sequence (PTS) selected to promote solubility of the peptide in the reaction solvent. 10 In a preferment of this option, the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly Preferably, the terminal sequence of the peptide is 'selected 15 from the group consisting of: GlyLysLysLysLysSerCys AlaAlaAlaAlaCys GlySerGlySerGlyCys CysSerLysLysLysLysGly CysAlaAlaAlaAla CysGlySerGlySerGly Preferably, F is a peptide selected from the List of-Peptides. 20 Preferably, F is a peptide selected from the group consisting of: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys WO 2009/035347 PCT/NZ2008/000239 22 GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValCys SerGInThrAsnAspLysHisLysArgAspCys Preferably, L is a glycerophospholipid. More preferably, L is a glycerophospholipid selected from the group consisting of: 1, 2-0-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) 5 and 1, 2 -0-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE). In a fifth aspect the invention provides a method of effecting qualitative and quantitative changes in the levels of peptide 10 expressed at the surface of cells and multi-cellular. structures including the step of: e contacting the cells or multi-cellular structures with a solution of a peptide-lipid construct of the second or 15 third aspects of the invention at a concentration and for a time and temperature sufficient to allow the construct. to incorporate into the surface. Preferably, the pep.tide-lipid construct is a construct of the 20 second aspect of the invention. Preferably the cells or multicellular structures are selected from the group consisting of: red blood cells; and embryos. More preferably, the cells or multicellular structures are 25 human cells or multicellular structures.
WO 2009/035347 PCT/NZ2008/000239 23 Preferably, the time and temperature is no greater than 2 hours at 37 0 C or 24 hours at 4 *C. In all aspects of the invention M is typically H, but may be 5 replaced by another monovalent cation such as Na*, K' or NH 4 *. In the description and claims of the specification the following acronyms, phrases and terms have. the meaning provided: 10 "Diagnostic marker" means a molecule, the presence of which in a body fluid of a subject is diagnostic of a phenotype or pathological condition of the subject. 15 "MNS blood group system " means blood group antigens or epitopes of those antigens and mutations which are present on either glycophorin A, glycophorin B or mutations which result in glycophorin A/B hybrids. 20 "Proximal terminal sequence" means that portion of the peptide sequence proximal to the amino- or carboxy- terminus of the peptide (F). "RBC" means red blood cells. 25 "Reactive antibody" means an immunoglobulin, the presence of which in a body fluid of .a subject is diagnostic of a phenotype or pathological condition of the subject. 30 "Via an oligomer of ethylene glycol" means -a polymer of ethylene glycol consisting of 2 to 32 mer and specifically excludes via a polymer of ethylene glycol consisting of greater than 32 mer.
WO 2009/035347 PCT/NZ2008/000239 24 "Water soluble" means a stable, single phase system is formed when the construct is contacted with water or saline (such as PBS) at a concentration of at least 100 pg/ml and in the 5 absence of organic solvents or detergents. The phrase is used synonymously with the term "water dispersible". Exemplifying embodiments of the invention are claimed and will now be described in detail with reference to the Figures of 10 the accompanying drawings pages. BRIEF DESCRIPTION OF DRAWINGS Figure 1. IH-NMR spectrum of the peptide-lipid construct designated DOPE 15 PEG,- Ala-Mal-Milt (K) (M13) (5 mg/ml in CD 3 0D/CDCl 3
/D
2 0/0.5M CF 3 COOD 60/20/10/1, 600 MHz, 30 *C, 6 ppm). Figure 2. MALDI TOF mass-spectrum of the peptide-lipid construct designated DOPE-PEG 6 - pAla-Mal-Milt (K) (M13) (2856:Peptide-DOPE (M+H); 2878: 20 Peptide-DOPE (M+Na); 2894:Peptide-DOPE (M+K); 2900:Peptide-DOPE (M+Na, Na salt); 2916:Peptide-DOPE (M+K, Na salt)). Figure 3. ESI mass-spectrum and analytical HPLC of the peptide SerSerGlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys of the peptide 25 lipid construct designated DOPE-PEG 6 -@Ala-Mal-Milt (K) (M13) Figure 4. 'H-NMR spectrum of the peptide SerSerGlnThrAsnAspLysHisLysArg AspThrTyrGlySerGlySerGlyCys of the peptide-lipid construct designated
DOPE-PEG
6 - 3Ala-Mal-Milt (K) (M13) (4..5 mg/ml in .D 2 0, 600 MHz, 30 *C, 6 ppm). 30 Figure 5. Photomicrographs of zona free embryos modified to incorporate the M2 peptide-lipid construct by contacting the embryos with a dispersion of the construct at a concentration of 1 mg/mL for 2 hours. The upper photomicrograph is the DIC image. The lower photomicrograph is the 35 fluorescent image showing 3.0+ fluorescence.
WO 2009/035347 PCT/NZ2008/000239 25 DETAILED DESCRIPTION In general terms, the invention provides peptide-lipid constructs of the structure (L-S-)iF(-S-L)j where: 5 F is a peptide; S is a spacer covalently linking F to L; L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including 10 glycerophospholipids; i and j are independently 0 or 1; and the use of these peptide-lipid constructs in diagnostic and therapeutic applications. 15 Where i is 0 and j is 1 the peptide-lipid constructs are of the structure: F-S-L 20 Where i is 1 and j is 0 the peptide-lipid constructs are of the structure: L-S-F 25 Where S is linked to F via the amino terminus of the peptide the construct is represented by the structure or substructure L-S-F. 30 Where S is linked to F via the carboxyl terminus of the peptide the construct is represented by the structure or substructure F-S-L.
WO 2009/035347 PCT/NZ2008/000239 26 Where S is linked to F via a sulphide bond formed via the sulfhydryl group of a Cys residue of the peptide the residue is identified with an underscore (Cys). 5 Where S is linked to F via a sulphide bond formed with one or more Cys residues of the peptide, the representation of the peptide-lipid construct by the structure L-S-F-S-L, L-S-F or F-S-L is not intended to imply the sulphide bond is formed exclusively with terminal Cys residues. 10 The use of the peptide-lipid constructs in diagnostic applications is illustrated with reference to the use of constructs including the substructure: 0 00 * o -- NH O '0 15 where M is a monovalent cation (M*), n is 6 to 14, * is other than H, and the peptide is selected from the group of peptides consisting of peptides included in the List of Peptides 20 provided on the following pages where z is an integer from 0 to 6. [followed by pages 27 & 28] WO 2009/035347 PCT/NZ2008/000239 27 N ~ NI N MI~j N N N NIitq N ic >1 0 (Di (ci ra) -1cci . i i a) H ~~H (o (a) H U H- i coO r-A m D - ( 0 4CDC CD I ~ CD > U) ID cn) a1) H H4 4 ) )q H U) H- M) Iu) m I U) U) 4 K C D : -4 F< F:a) 4c~ (c0 > < 4 U) U) r-4 a)in Ho Hc I co~ci ~ S ~~H HU) 4n n: >FI : >i~~~ >i 0)o0 U) 4-H H H H E- PD CD F:Z E-' H H >l> S-c c) m)~ -co c U4 0( ) (a S-c U-0 0 S-0 Sj- 0 A (i 5 A) 4 >1 m I ( o 0 u -i CD I - K40 Q4- E-4 1E-4 04 X, E-a CD~ >1 >I1 CD C j 4 042-f0 E-io H2L S-c E-i p,> ow S-( E-04 S:4 a)~U >iH H 1 n > E- U CDQD E-i 04 U) U) (j E-E- E-4 444 0 F1 p El 1C4D CD C H H 124 la4 H E E- E-4 N N (ci (ci (c xc c c u WO 2009/035347 PCT/NZ2008/000239 28 M NNN N N NN Co (0 JCr(C (aI (0 (0 mC mO~ md mC m d m no (Oa ( x X x~ X < P E1-- < E-1H FH E-~- F IHOC > -q M: E-- 0 H - CD 4 J f ': -C U) i) l >1~ () >1 i P- H- EIli E i E- K 1 H: E -1 CD > > F- E (Q4 Q4 Q4 U) 04 04 Q4 ) 0) > Ij0) 4-1 ro > >i nU U) U) .,I IU) U) $- 4 (-i .4 Q~H W I ) H H U) t) D 0) U) 1tn0 -10 0) U) U)Q~ .0 1 4 r 0 t0' 0 >1 4 U)U)Q. U) U) P ~O 04 >1 > : r- 4 P >,I H H FC ,- H- 54 34 a U) UU) ) , coU U) coIU) U) U) : 1> H H > 1 U >I H 1 >1 >,> H4 Hi( -I. ~~~M 04 CDDC I I C ~ C:4 U) I-) 1 4 j~ U)j4 4 Q Q >1 - 4 10I) CZ 0 1 U) >1 >1I >110 0) U) ( 4 $ 1 FZ LI4 i-q LIF2 Im C-D 0 CDI-i I-i a4 C 4JU -)U a) 4-) -4J U4) a U) >1 p -I 0~4 ~ ~ - 00 fr 1 C >1 >1 U) H i >1 I i- U) U) nU )U) U C~0 > O2 4 $4 U -' -D ~ F F C/) E- CD C U a) 0), -4~0 . CJ)E- E- H CO H- H- E- CDU CD (14 E CD CD CDI C9 CD CD If 1~>1 U) LI) j ) co) a)~ a) a)I U) U )m 4-) iU >1 >1 > U) U) > >1 II I I >1 >1 4 Q4 LA __ __ _ _ i_ _ __ WO 2009/035347 PCT/NZ2008/000239 29 The amino acid residues of peptides are identified according to Table 3 of Appendix 2 of Annex C of the Administrative Instructions under the Patent Cooperation Treaty dated 7 February 2007 and in accordance with the convention: 5
H
2 N-XaaXaaXaa......XaaXaaXaa-COOH There is a need for inexpensive and low level sensitivity test systems for a range of diagnostic markers in donated blood, in 10. transfusion recipients, or in antenatal patients (where the unborn child may be at risk of haemolytic disease), e.g. syphilis markers and markers of the MNS blood group system. A particular advantage provided by the invention is the opportunity to employ established blood typing platforms to 15 detect a range of peptide antigen-antibody interactions. The capital costs associated with establishing a new diagnostic assay may therefore be- avoided. Some clinically significant blood group antigens are rare (or 20 rare in some populations). For example mutations of the MNS blood group system resulting in Miltenberger antigens are rare in Europeans, but common in Asians. Being able to create antibody detection and identification panels requires that these antigens be present on the diagnostic screening cells. 25 Obtaining ells suitable for antibody screening/identification having rare antigens is therefore problematic. Being able to add to cells rare antigens prepared exogenously is therefore a major advantage. 30 According to the method of the invention epitope containing peptide sequences for a range of diagnostic markers, such as specific reacting antibodies, ('an be localized to the surface of red blood cells (RBCs). These modified RBCs may then be WO 2009/035347 PCT/NZ2008/000239 30 used on existing blood typing platforms to detect-blood antobodies or pathologies. Although the invention is illustrated with reference to the 5 modification of red blood cells and embryos the -outer surface of other cells and multi-cellular structures is contemplated. However, red blood cells are preferred for use in diagnostic assays because of the facility with which these-modified cells could be used in blood typing laboratories. 10 The level of peptide-lipid construct incorporated into the cell membrane of red blood cells is controlled by the concentration of the construct in the dispersion contacted with the suspension. The presence of diagnostic markers may 15 then be assessed by agglutination whether direct (induced by centrifugation of cells) or indirect (induced by adding an antibody directed against the. immunoglobulins of the subject). Other methods of assessment may be employed including, for example, rosetting (Indiveri et al 1979) and enzyme linked 20 immunosorbant assays (ELISA). In contrast with the preparation of constructs where the function (F) is a carbohydrate, the preparation of constructs where F is a peptide presents a combination of technical 25 difficulties. Firstly, it is desirable for the peptide (F). ligated to the L S or S-L moiety to be dispersible in the solvents used for the ligation chemistry. Overcoming this difficulty may require 30 the selection of a proximal terminal sequence (PTS) to promote solubility without modifying the desired biological properties of the construct,' WO 2009/035347 PCT/NZ2008/000239 31 Secondly, it is r for the construct (L-S-F-S-L, L-S-F or F-S L) to be dispersible in water, or at least a biocompatible medium such as buffered saline, according to the requirements of the proposed application (i.e. it is desirable for the 5 construct to be "water soluble" as defined herein). Overcoming this difficulty requires the selection of a spacer (S) to promote solubility of the construct. Thirdly, where the proposed application is the modification of 10 cells such as red blood cells (RBCs) for use in diagnostic applications, including use as quality controls in blood group typing or detection of diagnostic antibodies present in patient serum, it is required for the construct to be dispersible without participating in antigen-antibody cross 15 reactivity not specific to the diagnostic marker. Satisfying this requirement requires the identification of suitable structural motifs for the spacer (S) and proximal terminal sequence (PTS) when the latter is present, or the development of sample preparation procedures that neutralize or at least 20 substantially mitigate the undesired cross reactivity and likelihood of false positives. It should.also be noted that where the application is for use in the modification of the surface of cells or multi-cellular 25 structures (e.g. an embryo) with a view to promoting the association of the modified cell or modified multi-cellular structure with a target surface (e.g. the endometrium) exposing the cell or multi-cellular structure to solvents is incompatible with maintaining the cells or-multicellular 30 structures in a viable state. Theability to localise peptides to the .urface of cells or multi-cellular structures via a residue proximal to either the WO 2009/035347 PCT/NZ2008/000239 32 N- or C- terminus of the peptide may also allow the naturally occurring configuration of the peptide sequence relative to the cell surface to be approximated. The presentation of the peptide sequence in the tertiary (or quaternary) structure of 5 the parent polypeptide (or protein) may therefore be mimicked. Although not demonstrated here it is contemplated that peptides may be localised to the surface of cells via multiple residues. For example, where both a residue proximal to the 10 amino terminus and a residue proximal to the carboxyl terminus are used to localize the peptide, a "looped" configuration of the peptide may be promoted at the surface. The use of polyethylene glycol (PEG) as a spacer to promote 15 solubility is known. However, polymers of PEG may interfere with the expression and function of the peptide at the surface. In the peptide-lipid constructs of the invention an oligomer of ethylene glycol (6 to 14 mer) is selected as a component (Si) of the spacer (S) linking the lipid (L) and 20 peptide (F).. Oligomers of ethylene glycol impart less solubility'to peptide-lipid constructs of the structure L-S-F than polymers of PEG. The difficulty referred to above therefore arises 25 when it is desired to obtain peptide-lipid constructs that are dispersible in biocompatible solvents and can be used in. methods of effecting qualitative and quantitative changes in the levels of peptide expressed at the surface of cells and multi-cellular structures. 30 The properties of the peptide-lipid constructs must be such that they can be readily dispersed in biologically compatible media in the absence of solvents or detergents, but WO 2009/035347 PCT/NZ2008/000239 33 incorporate into the lipid bilayer of a membrane when a solution of the construct is contacted with a suspension of cells or multi-cellular structures. 5 Peptide-lipid constructs with these potentially conflicting properties are prepared by adopting the combination of structural motifs described here. -The preparation of the peptide-lipid constructs where S is linked to F via a sulphide bond formed with a terminal Cys residue of the peptide at the 10 carboxy-terminus of the peptide is preferred as the peptide is less prone to oxidation. Adopting the combinations of structural motifs in accordance. with the description provided here a range of peptides may be 15 prepared as peptide-lipid constructs for use in methods of effecting qualitative and quantitative changes in the levels of peptide expressed at the surface of cells and multi cellular structures. 20 It will be understood that for a non-specific interaction, such as the interaction between diacyl- or dialkyl glycerolipids or glycerophospholipids and a membrane, structural and stereo-isomers of naturally occurring lipids can be functionally equivalent. For example, it is 25 contemplated that diacylglycerol 2-phosphate could be substituted for phosphatidate (diacylglycerol 3-phosphate). Furthermore it is contemplated that the absolute configuration of phosphatidate can be either R or S. 30 Preparation of DOPE-PEG 6
-NH
2 (7) . DOPE-PEG 6
-NH
2 .(L-Si-NH 2 ) (7, 800 mg) was prepared byjthe method of SCHEME 1. To a stirred solution of DOPE (5) (36 mg, 0.0484 WO 2009/035347 PCT/NZ2008/000239 34 mmol) in dry CHC1 3 (3 ml) a solution of Fmoc-PEG-NOS (4) (237 mg, 0.0697 mmol (containing about 80% of active N oxysuccinimide ester)) in dry CHCl 3 (1 ml) and Et 3 NH (30 ml) was added. 5 The solution was stirred for 15 h at 20 oC, then Et 3 NH (3 ml) was added, and the mixture was maintained for at 8 h at 20*C. The solution was then diluted with toluene (10 ml), evaporated under reduced pressure (10 to 15 torr) and dried under vacuum. 10 The crude residue was dissolved in H 2 0/MeOH/AcOH mixture (10:5:1 (v/v/v), 3 ml) and the solution was slowly applied to a reverse phase C 16 column (15 ml, water) . Salts, N hydroxysuccinimide and H 2 N-PEG-DOPE (7) were eluted from the 15 column with MeOH/H 2 0 1:2 (v/v) (30 ml), 1:1 (v/v) (15 ml) and 2:1 (v/v) (15 ml) . Target H 2 N-PEG-DOPE (7) was eluted from the column with MeOH (30 ml) and then with MeOH to MeOH/CHCl 3 mixtures (4:1 (v/v), 3:1 (v/v), 2:1 (v/v) and 1:1 (v/v); 30 ml each) . Fractions containing H 2 N-PEG-DOPE (7) were combined, 20 evaporated under reduced pressure (10 to 15 torr) and dried under vacuum. The residue obtained as a thin film on the flask walls was extracted twice with hexane (2 x 5 ml) and dried under vacuum 25 to yield 143 mg of H 2 N-PEG-DOPE (7) (78% on DOPE) as a white solid. TLC: Rf= 0.62 (ethanol/water/pyridine/AcOH; 3:1:1:1 (v/v/v/v)). 1H-NMR (500 MHz, CD 3 0D, 30 'C): 6 = 5.541 (m, 4H; 2 -CH=CH-), 30 5.416 (m, 1H; OCH 2
CHCH
2 0), 4.624 (dd, J = 12 Hz, J = 3.2 Hz, 1H; CO-OCHCHCH 2 ), 4.373 (dd, J= 12 Hz, J = 6.6 Hz, 1H; CO
.OCHCHCH
2 ), 4.195 (t, J = 5.6 Hz, 2H; .,POCH 2
CH
2 N), 4.117 (m, 2H;
POCHCHCH
2 ), 3.968 (m, 4H; OCH 2
CH
2 0, OCH 2
CH
2 N), 3.932 (t, J= WO 2009/035347 PCT/NZ2008/000239 35 6.2 Hz, 2H; OCH 2
CH
2 CO), 3.827 (m, 272 H; (-OCH 2
CH
2 -)n, n = 68), 3.683 (m, 2H; OCH 2
CH
2 0), 3.622 (t, J= 5.6 Hz, 2H; OCH 2
CH
2 N), 3.397 (t, J = 5..0 Hz, 2H; OCH 2
CH
2 N), 2.678 (t, J = 6.2 Hz, 2H;
OCH
2
CH
2 CO), 2.519 (m, 4H; 2 CH 2 CO), 2.228 (m, 8H; 2 5 CH 2 CH=CHCH2), 1.801 (m, 4H; 2 CI 2
CH
2 CO), 1.508 (m, 40H; -CH 2 -), 1.096 (-t, 6H; 2 CH 3 ) ppm. Preparation of peptide-lipid constructs 10 Maleimido-derivatives of DOPE-PEG 6
-NH
2 were used for the preparation of peptide-lipid constructs (L-S-F) by the method of SCHEME 2 via the maleimide-thiol Michael addition reaction. Synthesis via the maleimido-derivatives of DOPE-PEG 6
-NH
2 has 15 particular advantages over synthesis via iodoacetate derivatives as difficulties and low yields as a consequence of oxidation of the sulfhydryl residues of the peptide and subsequent dimer formation. Reducing agents (e.g. tertiary phosphines) may be used during-conjugation. 20 Maleimido-derivatives were synthesized with 65 to 70% yields starting from N-oxysuccinimid esters of maleimidobutyric and maleimidopropionic acids (8a, 8b). An unexpected complication arose due-to the presence of excess.Bu 3 P which appeared to be 25 highly reactive towards the maleimide function. Phosphine was therefore used only in sub-equivalent amounts (0.1 to 0.2 - equivalents). 30 (followed by page 36] WO 2009/035347 PCT/NZ2008/000239 36 SCHEE 1 ((1) 0 * (3) + N N0 + H-N 0 0 o 0 (4) 0 cm 0 0 IOCHACH,::A CN 2
)
7 ON) 0 * \ / (6) * 7NA N 4N) ft0 0
NN
2 O (AH 2 1t::. CH i 7 WO 2009/035347 PCT/NZ2008/000239 37 Trifluoroethanol used as a co-solvent in the preparation of 10bC where the peptide was GlnThrAsnAspMetHisLysArgAspThrTyr GlySerGlySerGlyCys appeared to be highly efficient for 5 solubilization of both reactants. However, the solvent also caused unwanted acidification of the reaction medium which may inhibit the Michael reaction. The isolated yield of 10bC in this experiment was -25%. Preparation of 10aC where the. peptide was GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGly 10 Cys (DOPE-PEG 6 -@Ala-Mal-3MUTM (M3) ) carried out using DMSO .as co-solvent was more successful and provided a 43% yield. The same solvent strategy in the preparation of 10bC where the peptide was GlnThrAsnAspLysHisLysArgAspThrTyrSerSerGlnThrAsn 15 AspMetHisLysArgAspThrTyrAlaAlaAlaAlaCys (DOPE-PEG 6 -@3Ala-Mal PTS-Milt(K,M)) failed because the peptide supplied appeared to be very acidic and caused solubilization problems. The yield of 10bC in this experiment was only 23% and about half of the peptide was recovered. 20 Molecular weights for the peptide lipid constructs were determined to be:
DOPE-PEG
6 -@Ala-Mal-Milt (M) - 3029.48 25
DOPE-PEG
6 - fAla-Mal-Milt (K, M) - 4591.12 As expected for peptides bearing the glutamine residue at the N-terminus, all preparations contain variable amounts of 30 related pyroglytamyl derivatives, M-17 in MS, due to loss of NH3. The formation of related pyroglytamyl derivatives was mitigated in peptides with N-terminal Ser residues.
WO 2009/035347 PCT/NZ2008/000239 38 The use of the peptide-lipid constructs in methods for effecting qualitative and quantitative changes in the levels of peptide expressed at the surface of cells and multi cellular structures is illustrated with reference to the 5 serodiagnosis. Modification of red blood cells with peptide-lipid constructs (general method) 10 Red blood cells are modified by mixing 1 part by volume of washed packed red blood cells with 1 part by volume of peptide-lipid construct dispersed at a concentration of 10 to 1000 pg/ml in cell media (Celpresoll). 15 The suspensions are either: 1. incubated for 2 hours at 37 'C before being washed and suspended in a cell medium for serological analysis at a concentration of 0.8 to 3% (Method 1); or 20 2. incubated for 3 to 4 hours at room temperature (circa 25 *C) followed by 18. hours at 4 *C before' being washed and suspended in a cell medium for serological analysis at a concentration of 0.8 to 3% (Method 2). 25 Modification of red blood cells with DOPE-PEG 6 -Ala-Mal Milt (K) (MOO) 4.7 mg of the lipid-peptide construct DOPE-PEG 6 -@Ala-Mal 30 Milt(K) (MOO)was reconstituted in 0.47 ml of Celpresol" by sonicating for 10 min and allowing to stand for 1 hour to provide a clear 10 .rg/ml stock solution.
WO 2009/035347 PCT/NZ2008/000239 39 SCHEME 2 0 Om 00 0\, 0 (>7 CH 2 ). (Ba w=1; 8b w=2) 0 0
(CH
2 ),,H NH 0
F
0 N zf N. ON 0 0 ""~'(C (9a w=1; 9b w=2) Yj CXa + Gys (Xaa)~ or XaCy HN'CH 0 0 N ( , " AN I 0 =4H 2
.(CH
2 Y, s (CH 2 ) NH NH +- I n 0 0yCZ-(H) (l0aN w=1; lObN w=2)0 (Xaa) ~N \HC or 0 A0, 0 (..CH 2 L (CHb s C 2 ) N . N liO _______ Y 0 0 (l0aC w=l; lObC w=2) WO 2009/035347 PCT/NZ2008/000239 40 The stock solution was diluted two-fold to provide a solution of 5 mg/ml and a dilution series then prepared for the peptide-'lipid construct at the following concentrations: 5 1 mg/ml (1:5 dilution in Celpresol") 0.5 mg/ml (1:10 dilution in Celpresolm) 0.25 mg/ml (1:20 dilution in Celpresolml) 10 200 pl of Miltenberger negative red blood cells (Milt~ RBCs) were washed two times with PBS and one time with Celpresol m . 40 pl of a washed packed volume of Milt RBCs were mixed with 40 pl of a dilution of the peptide-lipid construct and 15 incubated for 2 hours at 37 'C. The modified RBCs were then washed with Celpresolm and stored in Celpresolm until used in tube serology testing (3 days and 24 days). 20 Tube serology testing of modified red blood cells Serological reactions are graded or.scored by either of two established systems (0 or '-' = no agglutination, 1+ or 3 = 25 very weak agglutination, 2+ or 5 = weak agglutination, 3+ or 8 = moderate strong agglutination, 4+ or 10/12 = strong agglutination) Serological platforms used are Tube (addition of reagents and 30 reactants into plastic or glass serology tubes and after appropriate incubations, washing and centrifugation observing reactions macroscopically by.eye and a 1OX magnification eyepiece and scoring) and BioVue" (addition of reactants into WO 2009/035347 PCT/NZ2008/000239 41 cassettes containing beads (including some reactants) and after appropriate incubations and centrifugation observing the reaction patterns traped within the Gel matrix). BioVue is the serological column agglutination platform of Ortho-Clinical 5 Diagnostics. Serum samples were available from 47 blood donors of negative antibody screen status. These samples were designated "negative samples", but not determined not to have anti 10 Miltenberger antibodies). Three serum samples known to have Miltenberger related antibodies T217, T6025, T5896. These samples were designated "positive samples", but not determined to have anti 15 antibodies-against the peptide of the peptide of the construct designated DOPE-PEG 6 -@Ala-Mal-Milt (K) (MOO). A suspension of 3 % modified RBCs was prepared in PBS and 30 pl of the suspension mixed with 30 pl serum sample. The 20 mixtures were then incubated for 45 min at 37 *C. Following incubation the RBCs were centrifuged for 10 s in an Immufugem (setting: "high") and observed for agglutination before being washed 3 times with PBS. 25 After washing one drop of Epiclonem anti-human globulin (AHG) was added and the tubes then centrifuged for 10 s in an Immufugem (setting: "high") . Tubes were then read and serology scores recorded.
WO 2009/035347 PCT/NZ2008/000239 42 [followed by page 42]Age of Concentration of modified DOPE-PEG 6 -pAla-Mal-Milt (K) (MOO) (mg/ml) RBCs (days) 1.0 0.5 25 Serum (n = 47) (n 21) (n 21) Negative AHG+ AHG- AHG+ AHG- AHG+ AHG 3 samples 1 46 0 21 0 21 Table 1. Summary of reactivity of samples of serum from 47 blood donors not expected to have anti-Miltenberger activity ("negative samples"). AHG+ means sample reacted by the anti-human globulin test. AHG- means sample is 5 unreactive. RBCs were modified with the peptide-lipid construct designated
DOPE-PEG
6 -I@Ala-Mal-Milt (K) at the concentrations indicated. Sera were tested against modified.RBCs following 3 days storage. Age of modified Concentration of RBCs DOPE-PEG 6 -PAla-Mal-Milt (K) (MOO) (mg/mi) (days) Serum 1.0 0.5 0.25 3 T217 2+'| 1+ 3 T6025 4+ 1 4+ . 4+ 3 T5896- 24 T217 - n.t. 24 T6025 2+ 2+ n.t. 24 T5896 - - n.t. 10 Table 2. Results by tube serology of 3 serums known to contain antibodies against antigens of the Miltenberger complex. Score results show sample -reactivity by the anti-human globulin test, 1+ = weak, 2+ = medium, 3+ = medium/strong, 4+ = strong, - means sample is unreactive. RBCs were modified with the peptide-lipid construct. at the concentrations indicated. 15 Sera were tested against modified RBCs following 3 days and 24 days storage. (n.t. - not tested).
WO 2009/035347 PCT/NZ2008/000239 43 Age of i modified Concentration of RBCs DOPE-PEG 6 -pAla-Mal-Milt (K) (MOO) (mg/ml) (days) Serum 1.0 0.5 0.25 3 T217 - 1+ 3 T6025 -1+ 2+ 1+ 3 T5896 24 T217 - 24 T6025 2+ 2+ 1+ 24 T5896 - Table 3. Results by Diamed column serology of 3 serums known to contain antibodies against the Miltenberger complex. Score results show sample 5 reactivity by the anti-human globulin test, 1+ = weak, 2+ = medium, 3+ = medium/strong, 4+ = strong, - means sample is unreactive. RBCs were modified with the peptide-lipid construct at the concentrations indicated. Sera were tested against modified RBCs following 3 days and 24 days storage. 10 Peptide inhibition A 5 mg/ml stock solution of the peptide GlnThrAsnAspLysHisLys ArgAspThrTyrCys dissolved in Celpresolm was prepared. A 4 pl 15 (20 pg peptide) volume of the stock solution was added to a 30 pl volume of each serum sample (Test). A 4 pl volume of Celpresolm was added to 30 pl -of each serum sample (Control). Serum samples (Test and Control) were then incubated at room temperature (RT) for 10 min. 20 A 30 pl volume of a 5% suspension of the modified RBCs was added to each sample.and incubated at 37 *C for 45 min. The incubated RBCs were then "ashed 3 times with PBS in an ImmufugeT. One drop of Epiclonem anti-human globulin (AHG) WO 2009/035347 PCT/NZ2008/000239 44 reagent was then added to each sample and the tubes centrifuged for 10 s in an. Immufuge7" (setting: "high") . Tubes were read and serology scores recorded. Concentration of
DOPE-PEG
6 - PA-la-Mal-Milt (K) (MOO) (mg/ml) Peptide Serum 1.0 0.5 T217 3+ 2+ CONTROL T6025 4+ 4+ T5896 T217 TEST T6025 T5896 5 Table 4. Results by tube serology of 3 serums known to contain antibodies against the Miltenberger complex and inhibited with peptide. Recorded scores show sample reactivity by the anti-human globulin test, 1+ = weak, 2+ = medium, 3+ = medium/strong, 4+ = strong, - means sample is 10 unreactive. RBCs were modified with the peptide-lipid construct at the concentrations indicated. [followed by page 45] 15 WO 2009/035347 PCT/NZ2008/000239 45 H C4 w U Y) 'V U) a)1 a)i C a) u- u ) 0 -, 4 'V In(1 V a)) a) 0) a)' 0) 4- ri HI 04 4) 04) 01 a) W 4 l 0) 0 4 0 4 HV H 4 04 -n 0J 4J coI ~ 4-) 4 I 4J ~ ~ V ' EH H a) ~ 0 a) a) 0) 41 4 j- ' a) 4-) r4 a-)4 00 a) a)'' 0) 0) a) ~ -- 'U "- U ~-P a - 4 - 1 ) oo 0% 0c a) 1:4 a) a) 0. U) H) U) o C r 0 0 0 UI4 0 a) 'Va) 'V 'O 0) Q4 ~ ~ ~ ~ 04 0 O 4U 00 13) o ) 0 1 0 01 . 0 4-) WO 2009/035347 PCT/NZ2008/000239 46 0 4 0U 0 0 ~4 o0 0 (14- > 1 UI) QL C 4 (D 0 CO ) m 4-) a) p 0)) CD C) CD C1 -H LO 0]I 04 i O 0) 0 0 U IN) H) CN 1 0 H4 >1 4 0 H 0 0 L r--H 0 Ci0 LO 1aD 4-40 HI U H N Cj \) C~H0 CN O 4 -4 - 4 -E - -J-F WO 2009/035347 PCT/NZ2008/000239 47 04 l c a4 a4 4 04 ro0 (D 0 m- U) U) H>1 >1 I4$ Q -H EIp E - 2: 04 I H a)E U) .~ 04 a) 4
K'
4 4 K H04 >H0 Y) U) 0 FZ4 04 : (304-H U) 4)JC U) jF 4-' (3 ) 4 4-)0 M 4J )V) U -) U)KK> F:) g F: U U) U) EJ 1 ) -1 1-4~Q) a W 41 Q4 044 0 I0 a)) 04 04' - F a U) F: F:D F:9 U U F: 0i U -H j U H 4-' 0 4 ~ 4 -,- '0.F: X a) a)) -0 - r. M4 i~ E- F: F: F iF 4 0 C) 4 4-)) 04 4J a) 0 - i a) ' 0- 14- U r-4( AK : b)) H- E- E- F:4 E (d-) -r- Fr- M n : ,l Es) I -H 1) (3) (3o WO 2009/035347 PCT/NZ2008/000239 48 x Pj 0 00 0 Ho 0 w C d CdD Hc 1 EO1 -H o -: C) i- a U)0 H 0 In 0 0 -) If CD ___ Cd Cdi C) IC01 Hn a, 4J 0 0 o CD C) 0 C- C. V_ a, -u -P -P 4J ICd ) 4 a 0 0 P $4 04 U) $C4 0d_54 0 - P 0OP 0- 0 U O PD U1 O 14 0 Cd - 0 0f 1 0 -Hj 0n C> 0 0 H -P U - U) >11 ~D ~>1 Wd 0 a) 0H (NH 44 - -4 d-0 El __ >1 0 r, Q0 Cd % L U) -Po CD 0CdC) 0 0 C)0 0 04 0 00 o HP ~~-~~-IH' t- riL 1 ) 0 *d 4) 0 0 4) 4-40 - 0 4J 0 0 -) a4 w . I p1 0 -r' E- U)- U E- Cd (D-) s 0~~ 4- 0 0 44 - 0 H -, 44 0 0 .0 HD 0) H4t CZ H - -H H) z EA 4- E- 4p irs WO 2009/035347 PCT/NZ2008/000239 49 The majority of polyclonal sera demonstrated cross reactivity with one or more modified red blood cell populations (Tables 8 and 9). 5 Where false positives were observed these could be substantially eliminated by pre-treatment of the sample of serum with the peptide of the peptide-lipid constructs (Table 10 and 11). Ml modified cells M2 cells vs serum Identity of sera #4 #5 #6 #2 #6 #B Serum alone 5 5 10 8 8 8 Serum + peptide 0 0 0 0 2 0 10 Table 10. Sera reactive with RBCs modified to incorporate the M1 peptide lipid construct or M2 peptide-lipid construct constructs by contacting the cells with a 500 pg/ml dispersion of the construct (Method 1) were "neutralised" with the peptide QTNDKHKRDTY and retested against the 15 modified cells. Sera were neutralized by adding 10 pL of 1 mg/ml solution of peptide to a 50 pL volume of sera and incubating for 30 minutes at 37 OC. Testing was performed using BioVuem cards. M13 modified cells Identity of sera #3 #42 #37 #34 Serum alone 8 8 8 8 Serum + peptide 0 0 0 0 20 Table 11. Sera reactive with RBCs modified to incorporate the M13 peptide-lipid construct by contacting the cells with a 500 pg/ml dispersion of the construct (Method 1) were "neutralised" with the peptide SSQTNDKHKRDTY and.retested against the modified cells. Sera were 25 neutralized by adding 10.pL of 1 mg/ml solution of peptide to a 50pL volume of sera and in.dibating for 30 minutes at 37 *C. Testing wa. performed using BioVue" cards.
WO 2009/035347 PCT/NZ2008/000239 50 Modification of embryos with the peptide-lipid construct designated DOPE-PEG6-fAla-Mal-PTS-Milt (K) (M2) The zona pellucida of day 3.5 embryos prepared as microdrops 5 were removed by incubation in 0.5% pronase solution for circa 5 minutes at 37 'C. The zona pellucida removed embryos were transferred to microdrops containing media alone and contacted with a dispersion of the peptide-lipid construct designated DOPE-PEG6-3Ala-Mal-PTS-Milt(K) (M2) at a concentration of 1 10 mg/ml for 2 hours. The dispersion of the peptide-lipid construct contained azide as an anti-microbial agent. The incubated embryos were washed four times in handling media and transferred to microdrops containing the Gam monoclonal .15 antibody (see Table 8) and incubated at 37 'C for 40 min. The embryos were then washed four times in handling media and transferred to microdrops containing secondary antibody (FITC anti-mouse)at a 1:50 dilution. 20 The microdrops were incubated at room temperature in the dark for 30 minutes before being washed four times in handling media, placed on microscope slides, and overlaid with mineral oil. The embryos were visualized using an Olympusm BX51 fluorescent microscope at 200 x magnification with WIB filter 25 550 nm emission wavelength. The scale used for grading fluorescence was 0 to 4+, where 0 is no fluorescence and 4+ is very bright fluorescence. The mean fluorescence of the modified embryos was 2+ versus zero for unmodified embryos. The grading of fluorescence is recorded in Table 12. 30 WO 2009/035347 PCT/NZ2008/000239 51 Mean Fluorescence* M2 FSL-peptide Media alone 2.0+ 0 Table 12. Fluorescence of embryos modified by contacting with the peptide-lipid construct designated DOPE-PEG6-sAla-Mal-PTS-Milt (K) (M2) (10 embryos per group; scale is 0 to 4+). 5 A mean fluorescence of 2+ was observed for the zona pellucida removed embryos modified to incorporate the peptide-lipid construct. designated DOPE-PEG6--3Ala-Mal-PTS-Milt (K) (M2). No fluorescence was observed for control embryos. The de 10 compaction of treated embryos was attributed to the presence of azide in the dispersion of the peptide-lipid construct. Although the invention has been described by way of exemplifying embodiments it should be appreciated that 15 variations and modifications may be made without 'departing from the scope of the invention. Furthermore where known equivalents exist to specific features, such equivalents are incorporated as if specifically referred to in this specification. 20 WO 2009/035347 PCT/NZ2008/000239 52
REFERENCES
Blume et~al (1993) Specific targeting with poly(thylene glycol) modified liposomes coupling of homing devices to the ends of the 5 polymeric chains combines effective target binding with long circulation times Biochimica et Biophysica Acto, 1149: 180-184 Chung et al (2004.) Casual Cell Surface Remodelling Using Biocompatible Lipid-poly(ethylene glycol) (n): Development of 10 Stealth Cells and Monitoring of Cell Membrane Behaviour in Serum supplemented Conditions J Biomed. Mater. Res, Part A, 70A/2:179 185 Haselgrubler et al (1995) Sythesis and Applications of a New 15 Poly(ethylene glycol) Derivative for the Crosslinking of Amines with Thiols Bioconjugate Chem, 6: 242-248 Hashimoto et al (1986) lodacetylated and biotinylated liposomes: Effect of spacer length on sulfhydryl ligand binding and avidin 20 precipitability Biochim Biophys Acta, 856: 556-565. Ishida et al (2001) Liposomes Bearing Polytheneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo Pharmaceutical Research, 18 (7): 1042-1048 25 Kato et al (2004) Rapid Proprotein anchoring into the membranes of mammalian cells using oelyl chain and polyethylene glycol derivatives 30 Kinsky et al (1983) An alternative procedure for the preparation of immunogenic liposomal model membranes J Immunol Method, 65: 295 306 Kung and Redemann (1986) Synthesis of carboxyacyl derivatives of 35 phosphatidylethanolamine and use as an efficient method for conjugation of protein to liposomes Biochim Biophys Acta, 862: 435-439 Legler et al (2005) Differential insertion of GPI-anchored GFPs 40 into lipid rafts of live cells FASEB J. 19, 73-75 Mannino et al (1993) Liposomes as adjuvants-for peptides: Preparation and use of immunogenic peptide-phospholipid complexes Liposome Technoljogy: 167-184 45 Martin et al (1990) Liposomes a Practical Approach, 163-182 WO 2009/035347 PCT/NZ2008/000239 53 Martin and Papahadjopoulos .(1982) Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem, 257: 286-288 5 Massaguer et al (2001) Synthesis of RGD Containing Peptides. Comparative Study of their Incorporation to the Surface of 5 Fluoruridine Loaded Liposomes. Journal of Liposome Research, 11(I):103-113 10 McHugh et al (1995) Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80) Proc. Natl. Acad. Sci. U. S. A. 92, 8059-8063 Medof et al (1996) Cell surface engineering with GPI-anchored 15 proteins FASEB J. 10, 574-586 Morandat et al (2002) Cholesterol dependent insertion of glycosylphosphatidylinositol-anchored enzyme Biochim. Biophys. Acta 1564, 473-478 20 New (1992) Liposomes: A Practical Approach Premkumar et al (2001) Properties of exogenously added GPI-anchored proteins following their incorporation into cells J. Cell-. Biochem. 25 82, 234-245 Ronzon et al (2004) Insertion of a glycosylphosphatidylinositol anchored enzyme into liposomes J. Membr. Biol. 197, 169-177 30 Shek and Heath (1983) Immune response mediated by liposome associated protein antigens III Immunogenicity of bovine serum albumin covelantly coupled to vesicle surface Immunology, 50: 101 106 35 Skountzou et al (2007) Incorporation of glycosylphospatidylinositol-anchored granulocyte-macrophage colony stimulating factor or CD40 ligand enhances imm.unogenicity of chimeric Simian Immunodeficiency Virus-like particles J. Virol. 81, 1083-1093 40 Winger et al (1996) Lipopeptide conjugates: biomolecular building blocks for receptor activating membrane-mimetic structures Biomaterials, 17: 437-441 45
Claims (2)
- 5. * Contacting a sample of the serum with a suspension of cells modified to incorporate a peptide-lipid construct of the structure (L-S-)iF(-S-L)j to provide a mixture; 10 * Incubating the mixture for a time and at a temperature sufficient to allow agglutination; and * Determining the degree of agglutination of the 15 cells in the mixture; where: F is a peptide comprising an epitope for the 20 reactive antibody; S is a spacer covalently linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids; and 25 i and j are independently 0 or 1, 2) The method claim 1 where the method includes the preliminary step of: 30 * Adding an amount of the peptide to the sample of the serum; WO 2009/035347 PCT/NZ2008/000239 55 where the amount of the peptide is sufficient to neutralize non-specific agglutination or confirm specificity of the reactive antibody. 5 .3) The method claim 1 where includes the intermediate step of: Adding an anti-subject globulin antibody to the mixture prior to determining the degree of 10 agglutination of the cells of the mixture. 4) The method claim 1 where the subject is a human. 5) The method claim 1 where the cells are red blood 15 cells. 6) The method claim 1 where the anti-subject globulin antibody is anti-human globulin (AHG) antibody. 20 7) The method claim 1 where the reactive antibody is reactive to an antigen selected from the group consisting of:' Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood group system). 25 8) The method claim 1 where S is a. spacer covalently linking F to L via an oligomer of ethylene glycol. 9) The method claim 1 where the structure of the peptide 30 lipid construct includes the substructure: WO 2009/035347 PCT/NZ2008/000239 56 0 0 * O-P-- NH NH * I n OM where M is a monovalent cation (M+), n is 6 to 14 and * is other than H. 5 10) The method claim 1 where the structure of the peptide lipid construct is either: (Xaa) Cus (Xaa) y 0 0 o OOO NH NH (C 2 )N S n o O * y0 0 0 10 or 0 O a NO (Xaa) o OM 0 O 15 where M is a monovalent cation (M4), n is 6 to 14, w is 1 or 2, the sum of x and y is greater than 5, z is greater than 5, and * is other than H. 11) The method claim 1 where the sum of i and j is 1. 20 WO 2009/035347 PCT/NZ2008/000239 57 12) The method claim 1 where F is a peptide including a proximal terminal sequence (PTS) selected to promote solubility of the peptide. 5 13) The method claim 12 where the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 1.4) The method claim 1 where F is a peptide comprising an 10 epitope of antigens selected from the.group consisting of: Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood group system). 15) The method claim 1 where F is a peptide selected from 15 the List of Peptides. 16) The method claim 1 where F is a peptide selected from the group consisting of: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyqys. GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyqys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValCys SerGlnThrAsnAspLysHisLysArgAspCy3 AlaAlaAlaAlaValMetTyrAlaSerSerGly GlySerGlySerGlyValMetTyrAlaSerSerGly WO 2009/035347 PCT/NZ2008/000239 58 17) The method claim 1 where L is a glycerophospholipid. 18) The method claim 1 where L is a glycerophospholipid 5 selected from the group consisting of: 1,2-0-dioleoyl sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2 0-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE). 10 19) A peptide-lipid construct of the structure: L-S-F where 15 F is a peptide; S is a spacer covalently linking F to L via an oligomer of ethylene glycol; and L is a lipid selected from the group consisting of 20 diacyl- and dialkyl-glycerolipids, including glycerophospholipids. 20) The peptide-lipid construct of claim 19 where the structure of the peptide-lipid construct includes the 25 substructure: o 0 0 fl 0 - - NH NH * UM where M is a monovalent cation (M*) ,;n is 6 to 14 and 30 * is other than H. WO 2009/035347 PCT/NZ2008/000239 59 21) The peptide-lipid construct of claim 19 where F is a -peptide including a proximal terminal sequence (PTS) selected to promote solubility of the peptide. 5 22) The peptide-lipid construct of claim 21 where the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 10 23) The peptide-lipid construct of claim 19 where the terminal sequence of the peptide is selected from the group consisting of: GlyLysLysLysLysSerCys AlaAlaAlaAlaCys GlySerGlySerGlyCys CysSerLysLysLysLysGly CysAlaAlaAlaAla CysGlySerGlySerGly 15 24) The peptide-lipid construct. of claim 19 where S is covalently linked to F via a sulphide bond formed with the.Cys residue of the peptide. 20 25) The peptide-lipid construct of claim 19 where S is covalently linked to F via a sulphide bond formed with a Cys residue of the peptide at or proximal to a terminus of the peptide. WO 2009/035347 PCT/NZ2008/000239 60 26) The peptide-lipid construct of claim 19 where S is linked to F via a sulphide bond formed with a Cys residue of the peptide at the carboxy-terminus of the 5 peptide. 27) The peptide-lipid construct of claim 19 where S is of the structure S 1 -S 2 -S 3 , Si is an oligomer of ethylene glycol and S 2 -S 3 is selected from the group consisting 10 of: 0 0 NH (CH 2 ) N R2 0 where R 1 is a terminal carbon -of S 1 , R 2 is the sulphur 15 of the Cys residue and w is 1 or 2. 28) The peptide-lipid construct of claim 19 where the structure of the peptide-lipid construct is: (Xaa).C s(Xaa)y 0 0 0 *0 -NH O NH (CH 2 )N 2 O* OM * O 20 0 where M is a.monovalent cation (M+), n is 6 to 14, w is 1 or 2, the sum of x and y is.greater than 5, and * is other-than H. 25 WO 2009/035347 PCT/NZ2008/000239 61 29) The peptide-lipid construct of claim 28 where n is 6. 30) The peptide-lipid construct of claim 28 where y is 0. 5 31) The peptide-lipid construct of claim 19 where F is a peptide comprising an epitope of antigens selected from the group consisting of: Glycophorin A, Glycophorin B, or mutations thereof (including the MNS blood group system). 10 32) The peptide-lipid construct of claim 19 where F is a peptide selected from the List of Peptides. 33) The peptide-lipid construct of claim 19 where F is a 15 peptide selected from the group consisting of: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValCys SerGlnThrAsnAspLysHisLysArgAspCys 34) The peptide-lipid construct of claim .19 where L is a glycerophospholipid. 20 35) The peptide-lipid construct of claim 19 where L is a glycerophospholipid selected from the group consisting of: 1,2-0-dioleoyl-sn-glycero-3 phosphatidylethanolamine (DOPE) -and 1,2-0-distearyl 25 sn-glycero-3-phosphatidylethanolamine (DSPE). WO 2009/035347 PCT/NZ2008/000239 62 36) A peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCy CH3(CH 2 ) 7 CHCH (CH 0 0 - NH 2li _C 2 3 >r O-P-O_, NH N s CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 O OM 0 5 where M is a monovalent cation (M*) and designated DOPE-PEG 6 -@3Ala-Mal-PTS -lMUTK) (M1) 37) A peptide-lipid construct of the structure: 10 GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys 0 O-- O OH CH3(CH2)7CHCH(CH21 O O N O NH N CH 3 (CH 2 ) 7 CHCH(CH 2 ) 3 0 o 0 where M is a monovalent cation (M*) and designated DOPE-PEG 6 -@Ala-Mal-PTS-2MUTK) (M2) 15 38) A peptide-lipid construct of the structure: GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCys 000 0 I CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 0-O NH N sO CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 O 0 20 where M is a monovalent cation (M+) and designated DOPE-PEG 6 -@Ala-Mal-PTS-3MUTM (M3) WO 2009/035347 PCT/NZ2008/000239 63 39) A peptide-lipid construct of the structure: SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys 0 00 0 CH 3 (CH 2 ) 7 CHCH (GH 2 ) 3o- O NO 6NH 30 0~0-N CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 0 0 0 5 where M is a monovalent cation (M+) and designated DOPE-PEG 6 - pAla-Mal-13MUTK (M13). 40) A peptide-lipid construct of the structure: ProAlaHisThrAlaAsnGluValCys .0 0 0 N H N sH N CH 3 (CH 2 ) 7 CHCH(CH 2 ) 3 O O--O NH O N CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 0 OM 0 10 0 where M is a monovalent cation (M*) and designated DOPE-PEG 6 - Ala-Mal-18Mur (M18) (n=6) 15 41) A peptide-lipid construct of the structure: SerGlnThrAsnAsphysHisLysArgAspCys 0 0 0 CH 3 (CH 2 ) 7 CHCH (CH 2 3 0 NH NH gN CH3 (CH 2 ) 7 CHCH (CH 2 ) 3{0 0 0 where M is .a monovalent cation (M*) and designated 20 DOPE- PEG 6 - PAla-Mal-2 1MUTK (M21) (n=6)". WO 2009/035347 PCT/NZ2008/000239 64 42) A peptide-lipid construct of the structure: GluGluThrGlyGluThrGlyGlnLeuValCy CH3 (CH2) CHCH (0 NH O II _0P-a _ NH-i CH3 (CH 2 ) 7 CHCH (CH 2 ) 3 0 OM O 0 5 where M is a monovalent cation (M*) and designated DOPE-PEG 6 -p Ala-Mal-Hil3 (M23) (n=6) 43) A peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrSerSerGlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyCy 0 0 0I CH 3 (CH 2 ) 7 CHCH(CH 2 )3 0 0- O NH s CH 3 (CH 2 ) 7 CHCH (CH 2 ) 30 0 M 10 0 where M is a monovalent cation (M*) and designated DOPE-PEG 6 - pAla-Mal-PTS-Milt (K,M) 15 44) A peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrCy 0 1 CH3 (CH2) 7CHCH (CH2) 3 O O-O H 4 NH k 0-P-0-~N NHNq 6 CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 0 O where M is a monovalent cation (M*) and designated 20 DOPE-PEG 6 - pAla-Mal-Milt (K) (MOO) WO 2009/035347 PCT/NZ2008/000239 65 45) A peptide-lipid construct of the structure: GlnThrAsnAspMetHisLysArgAspThrTyrCys 0 0 0 CH 3 (CH 2 ) 7 CHCH (CH2 O-O NH O NH N s CH 3 (CH 2 ) 7 CHCH (CH 2 ) 3 0 0 0 5 - where M is a monovalent cation (M*) and designated DOPE-PEG 6 - PAla-Mal-Milt (M) 46) A peptide-lipid construct of the structure: GlnThrAsnAspLysHisLysArgAspThrTyrSerSerGlnThrAsnAspMetHisLysArgAspThrTyrCy 30 0y CH2:-,O O1O CH 3 (CH2) 7 CHCH (C 2 ) H O Off -0- NH NH N s CH 3 (CH 2 ) 7 CHCH (CH 2 33N 0 10 0 where M is a monovalent cation (M+) and designated DOPE-PEG 6 -@PAla-Mal-Milt (K, M) 15 47) The peptide-lipid construct of claim 19 where the structure of the peptide-lipid construct is: 0 * 0 O 0 (Xaa)z Y ONH -- I no- or OM 0 O 0 20 where M is a monovalent cation (M*), n is 6 to 14, z is greater than" 5, and * is other than H. WO 2009/035347 PCT/NZ2008/000239 66 48) The peptide-lipid construct of claim 45 where n is 14. 49) The peptide-lipid construct of claim 45 where F is a peptide including a terminal sequence selected to 5 promote solubility of the peptide. 50) The peptide-lipid construct of claim 47 where the terminal sequence of the peptide is selected-from the group consisting of: 10 SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 51) The peptide-lipid construct of claim 45 where F is a peptide selected from the group consisting of: 15 (Xaa) zValMetTyrAlaSerSerGly; where z is the integer 4, 5 or 6. 52) The peptide-lipid construct of claim 45 where F is a 20 peptide selected from the group consisting of: SerLysLysLysLysGlyValMetTyrAlaSerSerGly AlaAlaAlaAlaValMetTyrAlaSerSerGly GlySerGlySerGlyValMetTyrAlaSerSerGly 53) The peptide-lipid construct of claim 45 where L is a glycerophospholipid. 25 54) The peptide-lipid construct of claim 45 where L is a glycerophospholipid selected from the group consisting WO 2009/035347 PCT/NZ2008/000239 67 of: 1,2-0-dioleoyl-sn-glycero-3 phosphatidylethanolamine (DOPE) and 1,2-0-distearyl sn-glycero-3-phosphatidylethanolamine (DSPE). 5 55) A peptide-lipid construct of the structure: CH 3 (CH 2 ) 7 CHCH (CH 2 )3 0 0 0 N H _ . O - GlySerGlySerGlyValMetTyrAlaSerSerGly CH 3 (CH 2 ) 7 CHCH (CH 2 )3 OM 0 where M is a monovalent cation (M+) and designated 10 DOPE-PEG 14 -Syph. 56) A method of preparing a peptide-lipid construct (F-S L) of claim 19 to 47 including the steps of: 15 e Preparing a maleimido-derivative of a precursor construct by reacting a maleimido-donating reagent with a precursor construct of the structure L-Si NH 2 ; and 20 0 Reacting the maleimido-derivative-of the precursor construct with a peptide (F) including a Cys residue and solubilised in a solvent. where: 25 L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerolipids, including glycerophospholipids; and '30 Si is selected from the group consisting of oligomers of ethylene glycol. WO 2009/035347 PCT/NZ2008/000239 68 57) The method of claim 54 where the structure of the peptide-lipid construct is: (Xaa) xC rs (Xaa)Y 0 0 * -- ONH ONH (CH 2 )Ns 0 OM * O 5 0 where n is 6 to 14, w is 1 or 2, the sum of x and y is greater than 5, and * is other than H. 10 58) The method of claim 54 where the maleimido-donating reagent is selected from the group consisting of: N oxysuccinimid ester of maleimidobutyric acid; and N oxysuccinimid ester of maleimidopropionic acid. 15 59) The method of claim 54 where Si is an oligomer of ethylene glycol selected from the group consisting of 6 to 14 mer PEG (PEG 6 to PEGia).. 60) The method of claim 54 where Si is PEG 6 . 20 61) The method of claim 54 where the solvent is selected from the group consisting of: trifluoroethanol; DMSO; or mixtures thereof. 25 62) The method of claim 54 where the Cys residue is a terminal Cys residue. WO 2009/035347 PCT/NZ2008/000239 69 63) The method of claim 54 where F is a peptide including a proximal terminal sequence (PTS) selected to promote .solubility of t-he peptide in the reaction solvent. 5 64) The method of claim 61 where the PTS of the peptide is selected from the group consisting of: SerLysLysLysLysGly AlaAlaAlaAla GlySerGlySerGly 65) The method of claim 54 where the terminal sequence of 10 the peptide is selected from the group. consisting of: GlyLysLysLysLysSerCys AlaAlaAlaAlaCys GlySerGlySerGlyCys CysSerLysLysLysLysGly CysAlaAlaAlaAla CysGlySerGlySerGly 66) The method of claim 54 where F is a peptide selected from the List of Peptides. 15 67) The method of claim 54 where F is a peptide selected from the group consisting of: GlnThrAsnAspLysHisLysArgAspThrTyrAlaAlaAlaAlaAlaCys GlnThrAsnAspLysHisLysArgAspThrTyrGlySerGlySerGlyCys GlnThrAsnAspMetHisLysArgAspThrTyrGlySerGlySerGlyys SerSerGlnThrAsnAspLysHisLysArgAspThrTyrCys WO 2009/035347 PCT/NZ2008/000239 70 ThrTyrProAlaHisThrAlaAsnGluValCys ProAlaHisThrAlaAsnGluValC2y SerGlnThrAsnAspLysHisLysArgAspCys 68) The method of claim 54 where L is a glycerophospholipid. 5 69) The method of claim 54 where L is a glycerophospholipid selected from the group consisting of: 1,2-0-dioleoyl-sn-glycero-3 phosphatidylethanolamine (DOPE) and 1,2-0-distearyl sn-glycero-3-phosphatidylethanolamine (DSPE). 10 70) A method of effecting qualitative and quantitative changes in the levels of peptide expressed at the surface of cells and multi-cellular structures including the step of: 15 e contacting the cells or multi-cellular structures with a solution of a peptide-lipid construct of any one of claims 19 to 55 at a concentration and for a time and temperature sufficient to allow the 20 construct to incorporate into the surface. 71) The method of claim 54 where the peptide-lipid construct is a construct of any one of claims 19 to
- 47. 25 72) The method of claim 54 where the cells or multicellular structures are selected from the group consisting of: red bl'od cells; and embryos. WO 2009/035347 PCT/NZ2008/000239 71 73) The method of claim 54 where the cells or multicellular structures are human cells or -multicellular structures. 5 74) The method of claim 54 where the time and temperature is no greater than 2 hours at -37 'C or 24 hours at 4 *C.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ56138107 | 2007-09-11 | ||
NZ561381 | 2007-09-11 | ||
NZ562476 | 2007-10-12 | ||
NZ56247507 | 2007-10-12 | ||
NZ569023 | 2008-06-06 | ||
NZ56902308 | 2008-06-06 | ||
PCT/NZ2008/000239 WO2009035347A1 (en) | 2007-09-11 | 2008-09-11 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2008297660A1 true AU2008297660A1 (en) | 2009-03-19 |
AU2008297660B2 AU2008297660B2 (en) | 2013-10-24 |
Family
ID=43325190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008297660A Ceased AU2008297660B2 (en) | 2007-09-11 | 2008-09-11 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101918841B (en) |
AU (1) | AU2008297660B2 (en) |
HK (1) | HK1145708A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2817877T3 (en) * | 2012-02-15 | 2021-04-08 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
WO2015109325A1 (en) | 2014-01-20 | 2015-07-23 | University Of Utah Research Foundation | Compositions and methods for modifying the surface of cells and methods of use |
WO2016080850A1 (en) * | 2014-11-21 | 2016-05-26 | Nicolai Vladimirovich Bovin | Multivalent ligand-lipid constructs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US20030229013A1 (en) * | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
NZ550705A (en) * | 2004-03-22 | 2010-12-24 | Kode Biotech Ltd | Synthetic membrane anchors |
-
2008
- 2008-09-11 CN CN2008801164590A patent/CN101918841B/en not_active Expired - Fee Related
- 2008-09-11 AU AU2008297660A patent/AU2008297660B2/en not_active Ceased
-
2010
- 2010-12-22 HK HK10111995.0A patent/HK1145708A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101918841B (en) | 2013-09-11 |
HK1145708A1 (en) | 2011-04-29 |
CN101918841A (en) | 2010-12-15 |
AU2008297660B2 (en) | 2013-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10082515B2 (en) | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | |
JP5580202B2 (en) | Functional lipid construct | |
AU2010203099B2 (en) | Synthetic Molecule Constructs | |
US20140371437A1 (en) | Cell surface coating with hyaluronic acid oligomer derivative | |
JP6368304B2 (en) | Functional liposomes useful for delivery of bioactive compounds | |
AU2008297660B2 (en) | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | |
AU2012207696B2 (en) | Biosurface engineering | |
US10919941B2 (en) | Functional lipid constructs | |
JP6679085B2 (en) | Compounds that promote fixation of cells to culture substrate | |
AU2013201431B2 (en) | Functional lipid constructs | |
Chekhonin et al. | Polyethylene glycol-conjugated immunoliposomes specific for olfactory ensheathing glial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 561381 11 SEP 2007 NZ; 569023 06 JUN 2008 NZ AND 562476 12 OCT 2007 NZ |
|
PC1 | Assignment before grant (sect. 113) |
Owner name: KODE BIOTECH LIMITED Free format text: FORMER APPLICANT(S): BOVIN, NICOLAI; WEINBERG, CRISTINA-SIMONA; HENRY, STEPHEN |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |